retatrutide type 2 diabetes trial is gaining attention in metabolic research for its triple agonist activity on GIP, GLP-1, and glucagon receptors. In this carousel, we summarize recent clinical study findings related to weight management, A new weight-loss drug called

Recent studies showed that while adherence to these drugs is improving, people tend to stop their treatment too soon

Gradual weight loss of 12 pounds per week allows the dermis to remodel progressively, reducing the severity of skin laxity

Some studies suggest a meaningful percentage of total weight loss may come from lean mass

These features make GLP-1 RAs an advantageous alternative to rapid-acting insulin for patients inadequately controlled on a long-acting basal insulin

What should I do if I vomit or cannot stay hydrated

Macro- and micronutrient losses and nutritional status resulting from 44 days of total fasting in a non-obese man